These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 18942159)

  • 1. Prediction of antisense oligonucleotide efficacy using aggregate motifs.
    Sipes TB; Freier SM
    J Bioinform Comput Biol; 2008 Oct; 6(5):919-32. PubMed ID: 18942159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TargetFinder: a software for antisense oligonucleotide target site selection based on MAST and secondary structures of target mRNA.
    Bo X; Wang S
    Bioinformatics; 2005 Apr; 21(8):1401-2. PubMed ID: 15598838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of sequence motifs significantly associated with antisense activity.
    McQuisten KA; Peek AS
    BMC Bioinformatics; 2007 Jun; 8():184. PubMed ID: 17555590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the efficacy of short oligonucleotides in antisense and RNAi experiments with boosted genetic programming.
    Saetrom P
    Bioinformatics; 2004 Nov; 20(17):3055-63. PubMed ID: 15201190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches for the sequence-specific knockdown of mRNA.
    Scherer LJ; Rossi JJ
    Nat Biotechnol; 2003 Dec; 21(12):1457-65. PubMed ID: 14647331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selecting signature oligonucleotides to identify organisms using DNA arrays.
    Kaderali L; Schliep A
    Bioinformatics; 2002 Oct; 18(10):1340-9. PubMed ID: 12376378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of antisense oligonucleotides based on multiple predicted target mRNA structures.
    Bo X; Lou S; Sun D; Shu W; Yang J; Wang S
    BMC Bioinformatics; 2006 Mar; 7():122. PubMed ID: 16526963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense technology: a selective tool for gene expression regulation and gene targeting.
    Sahu NK; Shilakari G; Nayak A; Kohli DV
    Curr Pharm Biotechnol; 2007 Oct; 8(5):291-304. PubMed ID: 17979727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.
    Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T
    Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decoding non-unique oligonucleotide hybridization experiments of targets related by a phylogenetic tree.
    Schliep A; Rahmann S
    Bioinformatics; 2006 Jul; 22(14):e424-30. PubMed ID: 16873503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of high-stringency DNA hairpin probes by partial gene folding.
    Strohsahl CM; Krauss TD; Miller BL
    Biosens Bioelectron; 2007 Sep; 23(2):233-40. PubMed ID: 17512187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy.
    Echigoya Y; Mouly V; Garcia L; Yokota T; Duddy W
    PLoS One; 2015; 10(3):e0120058. PubMed ID: 25816009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Widespread occurrence of antisense transcription in the human genome.
    Yelin R; Dahary D; Sorek R; Levanon EY; Goldstein O; Shoshan A; Diber A; Biton S; Tamir Y; Khosravi R; Nemzer S; Pinner E; Walach S; Bernstein J; Savitsky K; Rotman G
    Nat Biotechnol; 2003 Apr; 21(4):379-86. PubMed ID: 12640466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bias in nucleotide composition of antisense oligonucleotides.
    Smetsers TF; Boezeman JB; Mensink EJ
    Antisense Nucleic Acid Drug Dev; 1996; 6(1):63-7. PubMed ID: 8783797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense oligonucleotides in the treatment of bladder cancer.
    Glackin AJ; Gray SB; Johnston SR; Duggan BJ; Williamson KE
    Expert Opin Biol Ther; 2005 Jan; 5(1):67-77. PubMed ID: 15709910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of long oligonucleotides for gene expression microarrays using weighted rank-sum strategy.
    Hu G; Llinás M; Li J; Preiser PR; Bozdech Z
    BMC Bioinformatics; 2007 Sep; 8():350. PubMed ID: 17880708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AgeWa: an integrated approach for antisense experiment design.
    Arrigo P; Scartezzini P; Romano P
    IEEE Trans Nanobioscience; 2002 Dec; 1(4):167-71. PubMed ID: 16689207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion.
    Tanaka T; Chu CC; Paul WE
    J Exp Med; 1992 Feb; 175(2):597-607. PubMed ID: 1732418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.
    Rubenstein M; Tsui P; Guinan P
    Med Hypotheses; 2005; 65(5):905-7. PubMed ID: 16023790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.